ArticleClinical epidemiology2026
Cohort Profile: The Central Denmark Cancer Cohort.
Article in Clinical epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Cancer outcome studies frequently utilize registry data, which provide large-scale population-level information. However, these registries often lack detailed clinical information regarding comorbidities, lifestyle factors, and in-hospital treatments. The Central Denmark Cancer Cohort (CDCC) was established to address these limitations by linking medical and administrative registry data with clinical electronic medical records (EMR), to facilitate research to better understand the clinical course of cancer and its complications. Patients and Methods: The CDCC includes all patients with incident cancer, except non-melanoma skin cancer, diagnosed in the Central Denmark Region between 2012 and 2021, with complete follow-up through December 31, 2021. The CDCC was identified from the Danish Cancer Registry and linked via the Civil Personal Registration number to the Central Denmark Region Clinical Information System (CDRCIS) and to national registries, including the Danish National Patient Registry, National Prescription Registry, and Register of Laboratory Results for Research. We extracted data on demographics, lifestyle factors, comorbidities, treatments, and survival outcomes and assessed the availability of these data. Results: The CDCC included 68,028 patients with a median age of 68 years (interquartile range: 59-76 years); 47.2% were female. The most common cancers were prostate cancer (10,024 patients), breast cancer (9,100 patients), and non-small cell lung carcinoma (7,264 patients). At diagnosis, 98.0% of patients had laboratory test results available, 87.5% received at least one in-hospital medication, and 86.9% had at least one characteristic documented in CDRCIS. During median follow-up of 2.6 years, 37.8% of patients died and five-year survival was 59.0% (95% confidence interval: 58.6-59.4%). Data completeness varied by cancer type. Conclusion: The CDCC integrates clinical, lifestyle, and laboratory data with cancer registry information. By capturing factors typically unavailable in registry-based research, this platform offers a unique foundation for longitudinal studies on the clinical course of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.